Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 7:05 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1537–1560 of 2,085 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Open Label Extension Study Clear all

Conditions: Friedreich's Ataxia
Interventions: Interferon γ-1b; Drug
Lead sponsor: Amgen; Industry
Eligibility: 10 Years to 26 Years
Enrollment: 86 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 4
States / cities: Los Angeles, California • Gainesville, Florida • Iowa City, Iowa + 1 more

Conditions: Chronic Pain
Interventions: Oxymorphone ER; Drug
Lead sponsor: Endo USA Inc., a Keenova Therapeutics Company; Industry
Eligibility: 6 Years to 17 Years
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 13
States / cities: Little Rock, Arkansas • Stanford, California • Aurora, Colorado + 10 more

Conditions: Generalized Anxiety Disorder
Interventions: Placebo, DT120; Other · Drug
Lead sponsor: Definium Therapeutics US, Inc.; Industry
Eligibility: 18 Years to 74 Years
Enrollment: 245 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 13
States / cities: Little Rock, Arkansas • Los Angeles, California • Bradenton, Florida + 9 more

Conditions: Scleroderma, Systemic, Sclerosis, Systemic, Systemic Scleroderma, Systemic Sclerosis, Interstitial Lung Disease
Interventions: Pomalidomide (CC-4047), Placebo; Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 20
States / cities: Los Angeles, California • Rancho Mirage, California • Newark, Delaware + 17 more

Conditions: Crohn's Disease
Interventions: PF-00547659; Drug
Lead sponsor: Shire; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 268 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 47
States / cities: La Jolla, California • Orange, California • Lafayette, Colorado + 21 more

Conditions: Safety and Tolerability of Iloperidone
Interventions: iloperidone (oral tablet); Drug
Lead sponsor: Vanda Pharmaceuticals; Industry
Eligibility: 12 Years to 17 Years
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 10
States / cities: Costa Mesa, California • North Miami, Florida • Atlanta, Georgia + 7 more

Conditions: Bipolar Disorder, Mania
Interventions: divalproex sodium extended release; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 6 Years to 12 Years
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 1
States / cities: Cambridge, Massachusetts

Conditions: Rett Syndrome, RTT
Interventions: GWP42003-P; Drug
Lead sponsor: Jazz Pharmaceuticals; Industry
Eligibility: 2 Years to 18 Years
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 14
States / cities: Birmingham, Alabama • La Jolla, California • Aurora, Colorado + 11 more

Conditions: Alzheimer's Disease
Interventions: ABT-126; Drug
Lead sponsor: AbbVie (prior sponsor, Abbott); Industry
Eligibility: 55 Years to 90 Years
Enrollment: 343 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 9
States / cities: Long Beach, California • San Francisco, California • Hamden, Connecticut + 6 more

Conditions: Psoriatic Arthritis
Interventions: Alefacept, Methotrexate, Placebo; Drug
Lead sponsor: Astellas Pharma Inc; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 185 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2005
U.S. locations: 5
States / cities: Birmingham, Alabama • Wheaton, Maryland • Lake Success, New York + 2 more

Conditions: Relapsing Multiple Sclerosis
Interventions: Remibrutinib, Teriflunomide; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 1,007 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2030
U.S. locations: 50
States / cities: Phoenix, Arizona • Hanford, California • Los Angeles, California + 42 more

Conditions: Chronic Nonmalignant and Nonneuropathic Pain
Interventions: Hydrocodone bitartrate q24h film-coated tablets; Drug
Lead sponsor: Purdue Pharma LP; Industry
Eligibility: 18 Years and older
Enrollment: 922 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 98
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 81 more

Conditions: Primary Biliary Cholangitis
Interventions: Seladelpar, PTM Seladelpar, Cilofexor Dose B, PTM Cilofexor Dose A, PTM Cilofexor Dose B, Cilofexor Dose A; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 132 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2034
U.S. locations: 4
States / cities: Colorado Springs, Colorado • Lakewood Rch, Florida • Atlanta, Georgia + 1 more

Conditions: Papillomavirus Infections
Interventions: 9vHPV vaccine; Biological
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 9 Years to 26 Years
Enrollment: 700 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2029
U.S. locations: 14
States / cities: Daly City, California • Oakland, California • Roseville, California + 10 more

Conditions: Alzheimer's Disease
Interventions: AC-1204, Placebo; Drug
Lead sponsor: Cerecin; Industry
Eligibility: 66 Years to 90 Years
Enrollment: 418 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 82
States / cities: Birmingham, Alabama • Phoenix, Arizona • Hot Springs, Arkansas + 69 more

Conditions: Clostridioides Difficile Infection
Interventions: SER-109; Biological
Lead sponsor: Seres Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 263 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 97
States / cities: Dothan, Alabama • Sun City West, Arizona • Mather, California + 84 more

Conditions: Bardet-Biedl Syndrome, POMC Deficiency Obesity, PCSK1 Deficiency Obesity, LEPR Deficiency Obesity
Interventions: Setmelanotide; Drug
Lead sponsor: Rhythm Pharmaceuticals, Inc.; Industry
Eligibility: 2 Years to 5 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 3
States / cities: Aurora, Colorado • New York, New York • Marshfield, Wisconsin

Conditions: Crohn's Disease
Interventions: abatacept, placebo; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 451 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 37
States / cities: Birmingham, Alabama • Los Angeles, California • Sacramento, California + 33 more

Conditions: Breast Cancer
Interventions: trastuzumab (Herceptin®), anastrazole (Arimidex®); Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 208 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2009
U.S. locations: 20
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 16 more

Conditions: Hypereosinophilic Syndrome
Interventions: mepolizumab; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 78 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2010
U.S. locations: 10
States / cities: San Diego, California • Denver, Colorado • Bethesda, Maryland + 7 more

Conditions: Functional Constipation (FC), Chronic Idiopathic Constipation (CIC)
Interventions: Placebo for Linaclotide, Linaclotide; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 2 Years to 5 Years
Enrollment: 123 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 38
States / cities: Foley, Alabama • Phoenix, Arizona • Hot Springs, Arkansas + 33 more

Conditions: Multiple Myeloma in Relapse, Multiple Myeloma, Multiple Myeloma of Bone, Multiple Myeloma With Failed Remission
Interventions: MK-4002; Drug
Lead sponsor: Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA); Industry
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 8
States / cities: Gilbert, Arizona • Phoenix, Arizona • La Jolla, California + 5 more

Conditions: Rheumatoid Arthritis
Interventions: Andecaliximab, Placebo, Methotrexate, TNF Inhibitor; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 8
States / cities: Palo Alto, California • DeBary, Florida • Las Vegas, Nevada + 5 more

Conditions: Prader-Willi Syndrome
Interventions: DCCR; Drug
Lead sponsor: Soleno Therapeutics, Inc.; Industry
Eligibility: 4 Years and older
Enrollment: 77 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 17
States / cities: Orange, California • Palo Alto, California • San Diego, California + 14 more

Search by objective public record fields.

Safety, Tolerability and Efficacy of ACTIMMUNE® Dose Escalation in Friedreich's Ataxia Study

Open-Label Safety and Tolerability of Oxymorphone IR and ER in Opioid Tolerant Pediatric Subjects

A Phase 3 Trial of MM120 for Generalized Anxiety Disorder (Panorama)

Study of Pomalidomide (CC-4047) to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Effectiveness for Patients With Systemic Sclerosis With Interstitial Lung Disease

A Study To Monitor Long-Term Treatment With PF-00547659

Tolerability and Pharmacokinetics of Iloperidone in Adolescent Patients

Study of Depakote ER for the Treatment of Mania in Children Ages 6-12 With Bipolar Disorder

A Long-term Safety Study of Cannabidiol Oral Solution (GWP42003-P, CBD-OS) in Patients With Rett Syndrome

Safety and Tolerability Study Evaluating a New Treatment for Subjects With Mild to Moderate Alzheimer's Disease

A Placebo-controlled Study With an Extension Examining the Safety and Efficacy of Alefacept in Psoriatic Arthritis

Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS) (REMODEL-2)

Long-term Safety of Once-daily Hydrocodone Bitartrate (HYD) Tablets For Moderate to Severe Chronic Nonmalignant and Nonneuropathic Pain. Includes a 24-week Extension Period.

Study of Seladelpar and Cilofexor in Participants With Primary Biliary Cholangitis

Safety and Immunogenicity of Extended 2-dose Regimens of 9-valent Human Papillomavirus (9vHPV) Vaccine (V503-069)

AC-1204 26-Week Long Term Efficacy Response Trial With Optional Open-label Ext

ECOSPOR IV: An Open-Label Study Evaluating SER-109 in Recurrent Clostridioides Difficile Infection

Setmelanotide in Pediatric Participants With Rare Genetic Diseases of Obesity

A Study of Abatacept in Patients With Active Crohn's Disease

A Study to Evaluate the Efficacy and Safety of Herceptin® (Trastuzumab) in Combination With Arimidex® (Anastrozole) an Aromatase Inhibitor Compared to Arimidex® Alone in Patients With Metastatic Breast Cancer

Open-Label Extension Of Intravenous Mepolizumab In Patients With Hypereosinophilic Syndrome

A Study to Assess Adverse Events and Change in Symptoms With Linaclotide Versus Placebo in Pediatric Subjects, Ages 2 to 5 Years, With Functional Constipation

Study of HPN217 in Participants With Relapsed/Refractory Multiple Myeloma MK-4002 (MK-4002-001)

Andecaliximab as Add-On Therapy to a Tumor Necrosis Factor Inhibitor and Methotrexate Regimen in Adults With Moderately to Severely Active Rheumatoid Arthritis

Open-Label Extension Study of DCCR in Patients With Prader-Willi Syndrome